N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Phase 1 ClinicalTrials.gov

A Study of RO7890597 in Healthy Adult Volunteers

Sponsor: Genentech, Inc. • ClinicalTrials.gov ID: NCT07797478

Registry updated: 2026-10-16
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

This study will evaluate the safety, pharmacokinetics (PK), and activity of single and multiple doses of RO7890597 compared with placebo in healthy volunteers. The study includes single ascending dose (SAD) stage, multiple ascending dose (MAD) stage, food-effect and proton pump inhibitor (PPI) stages, and a supplemental drug-drug interaction (DDI) stage.

Interventions

  • RO7890597 (Drug)
    Participants will receive RO7890597 as per the schedule described in the protocol.
  • Placebo (Drug)
    Participants will receive matching placebo as per the schedule described in the protocol.
  • Rabeprazole (Drug)
    Participants will receive rabeprazole as per the schedule described in the protocol.
  • Itraconazole (Drug)
    Participants will receive itraconazole as per the schedule described in the protocol.

Eligibility criteria

Inclusion Criteria: * Agreement to adhere to the contraception requirements. * Body mass index of 18 to 30 kilograms per square meter (kg/m²). Exclusion Criteria: * Pregnant, breastfeeding, or intending to become pregnant during the study or required contraception period. * Treatment with investigational biologic therapy within 90 days or 5 elimination half-lives, whichever is longer, before study drug initiation. * Treatment with investigational non-biologic therapy within 28 days or 5 elimination half-lives, whichever is longer, before study drug initiation. * Treatment with immunosuppressive medication within 28 days or 5 elimination half-lives, whichever is longer, before study drug initiation. * Treatment with any vaccine within 14 days prior to initiation of study drug, or within 28 days for a live or live attenuated vaccine. * Poor peripheral venous access. * Major surgery within 28 days before study drug initiation or planned major surgery during the study. * Current infection or recent infection requiring antibiotics as defined in the protocol. * History of malignancy within 5 years before screening, except for specified adequately treated cancers. * History of clinically significant drug or food allergy.

Conditions

Healthy Volunteers

Locations

  • ICON (LPRA) - Lenexa — Lenexa, Kansas, United States
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record